Gropivirin tablets 500 mg. №20

Description

Gropivirin №20 Composition active ingredient Gropivirin:

inosine pranobex; 1 tablet contains 500 mg of inosine pranobex; excipients Gropivirin corn starch, mannitol (E 421), povidone (Kollidon 25), magnesium stearate.

DOSAGE FORM

Tablets.

MAIN PHYSICAL AND CHEMICAL PROPERTIES:

Gropivirin №20 tablets from white to yellowish-white, oval, biconvex, oblong, with a notch on one side, with a slight specific odor. PHARMACOLOGICAL GROUP Antiviral drugs for systemic use. ATX code J05A X05.

PHARMACOLOGICAL PROPERTIES

Pharmacological. Gropivirine is an antiviral agent with immunomodulatory properties. The drug Gropivirin normalizes (in an individual norm) the deficiency or dysfunction of cellular immunity, inducing the maturation and differentiation of T-lymphocytes and T1-helpers, potentiating the induction of lymphoproliferative responses in mitogen or antigen-active cells. Gropivirine models the cytotoxicity of T-lymphocytes and natural killer cells, the function of T8-suppressors and T4-helpers, and also increases the amount of immunoglobulin G and surface compliment markers. Gropivirin increases the synthesis of interleukin-1 (IL-1) and the synthesis of interleukin-2 (IL-2), regulates the expression of IL-2 receptors. Gropivirin significantly increases the secretion of endogenous interferon gamma and reduces the production of interleukin-4 in the body. Gropivirine enhances the action of neutrophils, chemotaxis and phagocytosis of monocytes and macrophages. Pharmacokinetics. After taking the drug Gropivirin orally at a dose of 1.5 g, the maximum concentration of inosine pranobex in the blood plasma is reached after 1:00 and is 600 μg / ml. In the body of inosine, pranobex is metabolized in the liver to form uric acid. The half-life of 4 (acetylamino) benzoate is 50 minutes, 1 (dimethylamino) -2-propanol is 3.5 hours. It is excreted by the kidneys in the form of metabolites. Indications Viral infections caused by herpes simplex virus types 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, measles virus, mumps virus, including in patients with immunodeficiency states; viral respiratory infections; papillomavirus infection of the skin and mucous membranes: genital warts, papillomavirus infection of the vulva, vagina and cervix (as part of complex therapy); acute viral encephalitis (as part of complex therapy); viral hepatitis (as part of complex therapy); subacute sclerosing panencephalitis (as part of complex therapy). Contraindications Hypersensitivity to the components of the drug Gropivirin, gout, hyperuricemia.

INTERACTION WITH OTHER DRUGS AND OTHER KINDS OF INTERACTIONS

Do not take Gropivirin at the same time as immunosuppressants. Care should be taken to prescribe the drug Gropivirine with xanthine oxidase inhibitors and agents that promote the excretion of uric acid, including diuretics – thiazide diuretics (such as hydrochlorothiazide, chlorthalidone, indapamide) and loop diuretics (such as furosemide, torasemide, ethacrynic acid). With the simultaneous use of Gropivirine with azidothymidine, nucleotide formation increases due to an increase in the bioavailability of zidovudine in blood plasma and an increase in intracellular phosphorylation in human blood monocytes.